Utilization of a micellar matrix for simultaneous spectrofluorimetric estimation of alfuzosin hydrochloride and vardenafil hydrochloride

• Published in: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy Molecular and biomolecular spectroscopy, 2022-02, Vol.266, p.120420, Article 120420
• Main Authors: Elama, Heba Samir, Shalan, Shereen M., El-Shabrawy, Yasser, Eid, Manal I., Zeid, Abdallah M.
• Format: Article
• Language: English
• Subjects: Alfuzosin hydrochloride; Biological fluids; Spectrofluorimetry; Tablets; Vardenafil hydrochloride
• ISSN: 1386-1425
• DOI: 10.1016/j.saa.2021.120420

[Display omitted] •Lower urinary tract symptoms (LUTS) are increasing in both ageing men and women.•Alfuzosin and vardenafil are recently co-administered for patients with LUTS.•First simultaneous method for alfuzosin & vardenafil based on spectrofluorimetry.•Micellar medium was used to enhance native fluorescence of drugs.•The method was applied to dosage forms and human biological samples. A sensitive and direct spectrofluorimetric method was developed for simultaneous quantitation of two co-administered drugs, namely, alfuzosin hydrochloride (AFH) and vardenafil hydrochloride (VRH). Both drugs exhibited native fluorescence properties that could be exploited to assay them in biological fluids with high sensitivity. Spectrofluorimetric analysis of AFH and VRH is based on excitation of both drugs at 265 nm where emission spectra were recorded separately for AFH and VRH at 380 and 485 nm, respectively. Micellar trends in analytical chemistry were adopted to minimize both environmental and occupational hazards, using distilled water and sodium dodecyl sulphate (serves as a micellar medium that enhanced the sensitivity of AFH and VRH) for analysis of both drugs in their raw materials, tablets, and human biological fluids (plasma and urine). Linearity ranges were 1.0–16.0 and 10.0–700.0 ng mL−1 for AFH and VRH, respectively. The proposed method was successfully assessed for analysis of AFH and VRH in spiked human plasma and urine samples over the following concentrations: 1.0–12.0 ng mL−1 and 4.0–400.0 ng mL−1 for both drugs, simultaneously with mean recoveries of 101.08 % and 102.06 % in plasma and 96.75 % and 92.8 % in urine. Statistical analysis of the practical results has proved quite good agreement and revealed there were no significant differences in the accuracy and precision with those obtained by the comparison methods. The proposed method was applied successfully to Prostetrol® and Powerecta® commercial tablets without interference with tablet additives.